AU3887789A - Method for suppressing immune responses by administering imexon - Google Patents

Method for suppressing immune responses by administering imexon

Info

Publication number
AU3887789A
AU3887789A AU38877/89A AU3887789A AU3887789A AU 3887789 A AU3887789 A AU 3887789A AU 38877/89 A AU38877/89 A AU 38877/89A AU 3887789 A AU3887789 A AU 3887789A AU 3887789 A AU3887789 A AU 3887789A
Authority
AU
Australia
Prior art keywords
imexon
administering
immune responses
suppressing immune
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU38877/89A
Other versions
AU619027B2 (en
Inventor
Uwe Bicker
Elmar Bosies
Rainer Haag
Dieter Herrmann
Wolfgang Kampe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUTOONCONA PHARMA GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU3887789A publication Critical patent/AU3887789A/en
Application granted granted Critical
Publication of AU619027B2 publication Critical patent/AU619027B2/en
Assigned to ROCHE DIAGNOSTICS GMBH reassignment ROCHE DIAGNOSTICS GMBH Request to Amend Deed and Register Assignors: BOEHRINGER MANNHEIM GMBH
Assigned to AUTOONCONA PHARMA GMBH reassignment AUTOONCONA PHARMA GMBH Alteration of Name(s) in Register under S187 Assignors: ROCHE DIAGNOSTICS GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to the use of 4-imino-1,3-diazabicyclo[3.1.0]hexan-2-one (imexon) as an immunosuppressive agent. Imexon selectively suppresses beta -lymphocyte activation and can be employed for the treatment of B-cell or plasma-cell leukaemia and neoplasms. Imexon is used in the treatment of those disorders in which polyclonal B-cell proliferation is of pathophysiological, symptomatic or clinical relevance such as, for example, for autoimmune diseases.
AU38877/89A 1988-07-28 1989-07-24 Method for suppressing immune responses by administering imexon Ceased AU619027B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3825667A DE3825667A1 (en) 1988-07-28 1988-07-28 USE OF IMEXON AS IMMUNOSUPPRESSIVE
DE3825667 1989-10-05

Publications (2)

Publication Number Publication Date
AU3887789A true AU3887789A (en) 1990-02-01
AU619027B2 AU619027B2 (en) 1992-01-16

Family

ID=6359767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38877/89A Ceased AU619027B2 (en) 1988-07-28 1989-07-24 Method for suppressing immune responses by administering imexon

Country Status (14)

Country Link
EP (1) EP0352652B1 (en)
JP (1) JP2848634B2 (en)
KR (1) KR0135757B1 (en)
AT (1) ATE117551T1 (en)
AU (1) AU619027B2 (en)
CA (1) CA1333771C (en)
DE (2) DE3825667A1 (en)
DK (1) DK175199B1 (en)
HU (1) HU206827B (en)
IE (1) IE66680B1 (en)
IL (1) IL91138A (en)
PH (1) PH26684A (en)
PT (1) PT91293B (en)
ZA (1) ZA895710B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1889943A (en) * 2003-12-08 2007-01-03 美国亚利桑那大学董事会 Synergistic anti-cancer compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528460A1 (en) * 1975-06-26 1977-01-13 Boehringer Mannheim Gmbh 1-Carbamoyl 2-cyano aziridine as immunostimulant - for therapy of bacterial and viral infections
DE2530398A1 (en) * 1975-07-08 1977-01-27 Boehringer Mannheim Gmbh ORGANIC CONNECTION
DE2736296A1 (en) * 1977-08-12 1979-02-22 Boehringer Mannheim Gmbh USE OF 2-CYAN-AZIRIDINE AND ITS DERIVATIVES FOR IMMUNESTIMULATION

Also Published As

Publication number Publication date
PT91293B (en) 1995-03-01
PH26684A (en) 1992-09-15
DE58908926D1 (en) 1995-03-09
IL91138A (en) 1994-10-21
HUT52378A (en) 1990-07-28
AU619027B2 (en) 1992-01-16
ATE117551T1 (en) 1995-02-15
EP0352652A3 (en) 1991-09-04
DK363389D0 (en) 1989-07-21
ZA895710B (en) 1990-04-25
JPH0288521A (en) 1990-03-28
CA1333771C (en) 1995-01-03
EP0352652A2 (en) 1990-01-31
DK363389A (en) 1990-01-29
JP2848634B2 (en) 1999-01-20
KR0135757B1 (en) 1998-04-23
KR900001369A (en) 1990-02-27
DE3825667C2 (en) 1991-06-27
DK175199B1 (en) 2004-07-05
HU206827B (en) 1993-01-28
IE892448L (en) 1990-01-28
PT91293A (en) 1990-02-08
DE3825667A1 (en) 1990-03-15
IE66680B1 (en) 1996-01-24
EP0352652B1 (en) 1995-01-25
IL91138A0 (en) 1990-03-19

Similar Documents

Publication Publication Date Title
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
CA2075904A1 (en) Method of treating pre-menstrual syndrome
MY111961A (en) Therapeutic method
AU6760987A (en) Method of treating alzheimer's disease
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
EP1298203A3 (en) Diagnosis and treatment of autoimmune diseases
CA2070281A1 (en) Improved treatment of autoimmune diseases by aerosol administration of auto antigens
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
EP0325129A3 (en) Disubstituted pyridines
MY104942A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-ones.
CA2060474A1 (en) Pharmaceutical use
AU622010B2 (en) Substituted 1,8-naphthyridines
AU3887789A (en) Method for suppressing immune responses by administering imexon
NZ216519A (en) Polycyclic compounds and pharmaceutical compositions
UA27055C2 (en) Medicinal preparation of immunoreplacement activity the basis of cellular suspension and method for treatment of acquired immune deficiency syndrome by the use of this preparation
EP0285883A3 (en) Bactobolin as a prophylactic or therapeutic agent for autoimmune diseases, and as an immuno-suppressive agent
FR2699920B1 (en) Imidazo [2,1-b] benzothiazole-3-acetamide derivatives, their preparation and their therapeutic use.
AU8864791A (en) Antibodies and methods for diagnosis and treatment of diabetes
ES2096559T3 (en) INTERFERON GAMMA HUMANO, PROCEDURE FOR THE PREPARATION OF SUCH INTERFERON GAMMA HUMANO, AND ITS USE.
FR2700546B1 (en) Imidazo [2,1-b] benzoxazole-3-acetamide derivatives, their preparation and their therapeutic use.
MY106961A (en) Antiviral tetrahydroimidazo[1,4] benzodiazepines
AU636421B2 (en) Method for the treatment of glaucoma
ES2062351T3 (en) TRIAZOLE DERIVATIVES (4,5-C) PIRIDINE ANTICONVULSIVES.
FR2699174B1 (en) Derivatives of 3- (quinoline-6-yl-methyl) -4H-imidazol-4-one, their preparation and their therapeutic use.

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ROCHE DIAGNOSTICS GMBH

Free format text: FORMER NAME WAS: BOEHRINGER MANNHEIM GMBH

PC Assignment registered

Owner name: AUTOONCONA PHARMA GMBH

Free format text: FORMER OWNER WAS: ROCHE DIAGNOSTICS GMBH